Agomelatine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Agomelatine: From Depressive Disorders to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Agomelatine is an antidepressant originally used for unipolar depression, endogenous depression, major depressive disorder and anxiety disorder. The TxGNN model's top-ranked prediction is benign paroxysmal torticollis of infancy, but this prediction has 0 clinical trials and 0 publications behind it. It is a model prediction only. Among the other top-10 predictions, the depression-related ones (melancholia, neurotic depression, dysthymic disorder) have literature support, but this is largely an overlap with the existing indication rather than true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record. The knowledge graph lists unipolar depression, endogenous depression, major depressive disorder and anxiety disorder |
| Predicted New Indication | Benign paroxysmal torticollis of infancy |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for the original indication is not available in the data compiled for this report. From the literature, agomelatine is an agonist of melatonin MT1 and MT2 receptors and an antagonist of the serotonin 5-HT2C receptor. Together these actions may normalise circadian rhythms, improve slow-wave sleep and increase dopamine and noradrenaline release in the prefrontal cortex. Pharmacology records also list activity at 5-HT2A and 5-HT2B receptors.
For the top-ranked prediction, benign paroxysmal torticollis of infancy, no mechanistic link was identified. It is a childhood disorder in the migraine spectrum, and the use of agomelatine in children is not established. The very high score is therefore best treated as an unverified model output.
Other predictions fall into three groups:
- Anxiety-spectrum (agoraphobia, neurotic disorder): A plausible biological link exists through 5-HT2C antagonism and melatonergic modulation, since anxiety disorder is already among the original indications. No condition-specific trials or literature were retrieved.
- Depressive spectrum (melancholia, neurotic depression, dysthymic disorder): These are subtypes of, or closely related to, major depressive disorder, where agomelatine is already used. The evidence is largely aggregated antidepressant data.
- Rare genetic syndromes (Ohdo syndrome and variants, Ohdo-type blepharophimosis, Keppen-Lubinsky syndrome, ligneous conjunctivitis): There is no plausible mechanistic link, and the high scores likely reflect network artefacts.
Clinical Trial Evidence
Currently no related clinical trials registered for the top-ranked prediction or for any other top-10 prediction.
Literature Evidence
The top-ranked prediction (benign paroxysmal torticollis of infancy) has no related literature. The table below shows literature for the most evidence-rich predictions, melancholia and dysthymic disorder. Most of it is class-level antidepressant evidence rather than disease-specific data.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29477251 | 2018 | Network meta-analysis (RCTs) | Lancet | Compares efficacy and acceptability of 21 antidepressants in acute adult major depressive disorder |
| 36253442 | 2023 | Systematic review / meta-analysis | Molecular Psychiatry | Network meta-analysis of antidepressants in the maintenance phase of major depressive disorder |
| 21527126 | 2011 | Meta-analysis of RCTs | J Clin Psychiatry | Antidepressants as a class are effective in dysthymia versus placebo (not agomelatine-specific) |
| 41679391 | 2026 | Systematic review / meta-analysis | J Affect Disord | Insomnia symptoms in depressed patients treated with agomelatine, mirtazapine and trazodone |
| 19708725 | 2009 | Review | CNS Drugs | Agomelatine efficacy at each phase of antidepressant treatment |
| 24033095 | 2013 | Review | Expert Opin Drug Saf | Agomelatine is an effective antidepressant with relatively mild side effects |
| 23037643 | 2012 | Review | J Neuropsychiatry Clin Neurosci | Novel mechanisms of action of agomelatine, linking circadian and sleep regulation to depression |
| 40129874 | 2025 | Narrative review | PCN Reports | Agomelatine among drugs showing promising anti-anhedonic effects |
| 25255870 | 2014 | Review | Curr Drug Metab | Safety and tolerability of agomelatine, with a focus on hepatotoxicity |
| 38043099 | 2023 | Case series | Acta Biochim Pol | Sertraline and agomelatine in hemodialysis patients with depression (low-grade evidence) |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13770P | VALDOXAN Tablet 25mg | Film-coated tablet (oral) | Not stated in the licence record |
Safety Considerations
- Hepatotoxicity: The literature reports severe hepatotoxic adverse reactions with agomelatine, including rare fatal hepatic failure (PMID 25255870). Liver function monitoring is generally advised.
- Drug Interactions: No specific drug-drug interaction records were found. Only pharmacological target interactions were listed: 5-HT2A, 5-HT2B, 5-HT2C, MT1 and MT2 receptors.
- Paediatric use: Use of agomelatine in children is not established, which matters for the top-ranked prediction, a disorder of infancy.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, benign paroxysmal torticollis of infancy, has a very high model score but no trials, no literature, no mechanistic rationale and an unestablished paediatric profile (Evidence Level L5). The depression-related predictions (melancholia, neurotic depression, dysthymic disorder) have the most literature (L2–L3), but they largely overlap with the existing indication, so they are better framed as research questions than as new repurposing opportunities.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA record, which is a blocking gap for safety screening
- Mechanism of action data from DrugBank
- Mechanistic and clinical rationale for benign paroxysmal torticollis of infancy, if it is to be pursued
- Paediatric safety and dosing data
- Agomelatine-specific trials for dysthymic disorder, agoraphobia and other anxiety-spectrum conditions, as these are the most plausible directions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.